AbbVie Inc. (NYSE:ABBV) Receives $245.84 Consensus PT from Brokerages

AbbVie Inc. (NYSE:ABBV) has been assigned an average recommendation of “Moderate Buy” from the twenty-four ratings firms that are presently covering the stock, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $245.8421.

ABBV has been the subject of a number of recent research reports. Morgan Stanley boosted their price objective on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a report on Friday, December 12th. UBS Group increased their price target on AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the company an “overweight” rating in a report on Thursday, October 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. Finally, Piper Sandler restated an “overweight” rating and issued a $289.00 price target (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th.

Institutional Trading of AbbVie

Several large investors have recently made changes to their positions in ABBV. Conning Inc. increased its position in shares of AbbVie by 7.1% during the second quarter. Conning Inc. now owns 191,023 shares of the company’s stock valued at $35,458,000 after acquiring an additional 12,690 shares in the last quarter. Diversified Trust Co boosted its stake in AbbVie by 23.6% during the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after purchasing an additional 10,891 shares during the last quarter. Dohj LLC boosted its stake in AbbVie by 41.8% during the 2nd quarter. Dohj LLC now owns 4,529 shares of the company’s stock valued at $802,000 after purchasing an additional 1,335 shares during the last quarter. Permanent Capital Management LP bought a new stake in shares of AbbVie in the 3rd quarter worth $720,000. Finally, First Hawaiian Bank lifted its holdings in shares of AbbVie by 0.8% during the second quarter. First Hawaiian Bank now owns 7,556 shares of the company’s stock valued at $1,403,000 after purchasing an additional 60 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of NYSE ABBV opened at $229.26 on Friday. The firm has a market cap of $405.19 billion, a price-to-earnings ratio of 173.68, a P/E/G ratio of 0.96 and a beta of 0.36. The stock’s fifty day moving average price is $226.69 and its two-hundred day moving average price is $213.94. AbbVie has a one year low of $164.39 and a one year high of $244.81.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the business posted $3.00 earnings per share. AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts anticipate that AbbVie will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.0%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is 496.97%.

Key Stores Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Signed a licensing/option deal with Zelgen around a T‑cell engager worth up to $1.1B, strengthening AbbVie’s oncology pipeline and potential future revenue streams. New year sees Abbvie, Zelgen in $1.1B T-cell engager deal
• Positive Sentiment: Zelgen Pharma confirmed a licensing option agreement with AbbVie, reiterating the near-term deal structure that adds option value to AbbVie’s immuno‑oncology portfolio. Zelgen Pharma inks licensing option agreement with AbbVie
• Positive Sentiment: AbbVie (and peers) are acquiring/licensing clinical‑stage cancer assets in multiple deals, accelerating near‑term pipeline growth without full internal development cost. AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals
• Positive Sentiment: Neuroscience franchise (Botox, Vraylar, migraine drugs) now contributes >17% of revenue and is fueling double‑digit sales growth, supporting AbbVie’s top line even as other areas reset. Here’s How AbbVie’s Neuroscience Portfolio Is Aiding Top-line Growth
• Positive Sentiment: Partner performance (Ironwood’s beat tied to AbbVie‑partnered Linzess) highlights durable royalties/partner cash flow from legacy assets. Ironwood beats on 2026 outlook thanks to AbbVie-partnered Linzess
• Positive Sentiment: Wall Street Zen changed coverage to a Buy, an analyst upgrade that can support near‑term investor demand. AbbVie (NYSE:ABBV) Cut to Buy at Wall Street Zen
• Neutral Sentiment: Analysts and previews expect AbbVie’s upcoming Q4 report to show double‑digit EPS growth; the print will be a key near‑term catalyst. What to Expect From AbbVie’s Next Quarterly Earnings Report
• Neutral Sentiment: Additional earnings previews reiterate expectations for strong bottom‑line growth, making the earnings release the primary short‑term focus. What to Expect From AbbVie’s Next Quarterly Earnings Report
• Neutral Sentiment: Balanced analyst commentary: some see an attractive setup for 2026 given growth and dividends, but note company risks. AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026
• Negative Sentiment: Valuation concerns: analysts note recent rally but argue ABBV may not be a bargain given a high P/E and limited margin for upside absent strong surprises. AbbVie’s Rally Looks Convincing — But The Stock Is Not A Bargain
• Negative Sentiment: Macro/rate risk: commentary to dividend investors warns that shifting Treasury issuance and shorter maturities make dividend stocks more sensitive to Fed policy — a potential headwind for high‑yield pharma names. My Most Important Warning To Dividend Investors For 2026

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.